Preparation of Electrospun Fibers for Sequential Administration of ART-EGCG and Its Synergistic Anti-liver Cancer Effect
CHEN Yanhao1,2,3,4, PENG Yan1,3,4, LIU Huijun1,3,4, WANG Shengnan1,3,4, YANG Yanling1,3,4, DAI Fangyin1,2,3,4,*, LI Zhi1,3,4
1 College of Sericulture, Textile and Biomass Sciences, Southwest University, Chongqing 400715, China 2 State Key Laboratory of Resource Insects, Southwest University, Chongqing 400715, China 3 Chongqing Engineering Technology Research Center of Biomaterial Fiber and Modern Textile, Southwest University, Chongqing 400715, China 4 Key Laboratory of Sericulture Biology and Genetic Breeding, Ministry of Agriculture, Southwest University, Chongqing 400715, China
Abstract: In order to inhibit the recurrence of liver cancer after surgery, local administration is often used to inhibit the growth of cancer cells and tumor formation. Based on the anti-cancer mechanism of artemisinin (ART) and epigallocatechin gallate (EGCG), the synergistic inhibitory effect of the two drugs on hepatocellular carcinoma cells was studied, and the results showed that the optimal sequence of sequential administration was ART-EGCG, the optimal administration time was 15 h+9 h, the optimal dosing ratio of ART and EGCG was 1∶1, and the optimal administration concentration was 25 μg/mL, which had a good synergistic inhibitory effect on hepatocellular carcinoma cells. Based on the synergistic inhibition effect of the two drugs’ delivery, coaxial electrospinning technology was used to design and fabricate the nanofibrous membrane with core-shell structure by mixing 15wt% PLGA and ART as the cortexal spinning solution, and 10wt% PEG and EGCG mixed as the core spinning solution. The prepared drug-loaded electrospun nanofibrous membrane with core-shell structure could effectively regulate the sequential release of ART and EGCG, and synergistically inhibit the growth and proliferation of hepatocellular carcinoma cells. The inhibition rate of the prepared drug-loaded electrospun membrane with core-shell structure on HepG2 cells was (38.66±4.12)% at 24 h.
陈彦昊, 彭艳, 刘惠军, 王胜男, 杨艳玲, 代方银, 李智. ART-EGCG序贯给药静电纺丝纤维的制备及协同抗肝癌效果研究[J]. 材料导报, 2025, 39(20): 24080226-6.
CHEN Yanhao, PENG Yan, LIU Huijun, WANG Shengnan, YANG Yanling, DAI Fangyin, LI Zhi. Preparation of Electrospun Fibers for Sequential Administration of ART-EGCG and Its Synergistic Anti-liver Cancer Effect. Materials Reports, 2025, 39(20): 24080226-6.
1 Sharifi-Rad M, Pezzani R, Redaelli M, et al. Molecules, 2020, 25(3), 467. 2 Wang H G, Cai K, Han X L. Acta Universitatis Medicinalis Anhui, 2019, 54(10), 1540(in Chinese). 王惠国, 蔡珂, 韩鑫龙. 安徽医科大学学报, 2019, 54(10), 1540. 3 Efferth T. Biochemical Pharmacology, 2017, 139, 56. 4 Chou Shih-Feng, Carson Daniel, Woodrow Kim A. Journal of Controlled Release, 2015, 220, 584. 5 Feng B Y. Special Wild Economic Animal and Plant Research 2020, 42(1), 6(in Chinese). 冯冰玉. 特产研究, 2020, 42(1), 6. 6 Zhao X, Zhao J W, Lin Z Y, et al. Colloids and Surfaces B-Biointerfaces, 2015, 130, 1. 7 Li G D. Academic Journal of Second Military Medical University, 1998(3), 98(in Chinese). 李国栋. 第二军医大学学报, 1998(3), 98. 8 Liao Y J, Hu C P. Medical Science Journal of Central South China, 2012, 10(2), 132(in Chinese). 廖音娟, 胡长平. 中南医药, 2012, 10(2), 132. 9 Zhang Y. Chinese Journal of Cancer Biotherapy, 2014, 21(1), 38(in Chinese). 张勇. 中国肿瘤生物治疗杂志, 2014, 21(1), 38. 10 Li X Y, Wu Z P, Wang M X. Chinese Herbal Medicines, 2019, 50(13), 3217(in Chinese). 李晓阳, 吴志平, 王梦馨. 中草药, 2019, 50(13), 3217. 11 Chen J, Wang X B, Zhang Y, et al. Biomaterials, 2021, 266, 120457. 12 Guo J P. Journal of Shanxi Medical University, 2017, 48(2), 97(in Chinese). 郭佳培. 山西医科大学学报, 2017, 48(2), 97. 13 Nishikawa T, Nakajima T, Moriguchi M, et al. Journal of Hepatology, 2006, 44(6), 1074. 14 Xu X Y, Zhao C N, Cao S Y, et al. Critical Reviews in Food Science and Nutrition, 2020, 60(10), 1693. 15 Xue J J, Wu T, Dai Y Q, et al. Chemical Reviews, 2019, 119(8), 5298. 16 He C G, Gao Y J, Li Z. China Biotechnology, 2007(2), 46(in Chinese). 何晨光, 高永娟, 赵莉. 中国生物工程杂志, 2007(2), 46. 17 Shi Y L, Zhang J H, Xu S X, et al. Journal of Biomaterials Science-Polymer Edition, 2013, 24(5), 551. 18 Li X L, Xu F N, He Y, et al. Advanced Functional Materials, 2020, 30(45), 2004851. 19 Li X L, He Y, Hou J W, et al. Small, 2020, 16(9), 1902262. 20 Bimonte S, Albino V, Piccirillo M, et al. Drug Design Development and Therapy, 2019, 13, 611. 21 Li J N, Xu W G, Li D, et al. ACS Nano, 2018, 12(7), 6685. 22 Chou T C. Cancer Research, 2010, 70(2), 440. 23 Volpe-Zanutto F, Ferreira L T, Permana A D, et al. Journal of Controlled Release, 2021, 333, 298. 24 Wang J, Windbergs M. European Journal of Pharmaceutical Sciences, 2018, 124, 71. 25 Bonadies I, Maglione L, Ambrogi V, et al. European Polymer Journal, 2017, 89, 211.
渝公网安备50019002502923号 版权所有：《材料导报》编辑部
2025, Vol. 39 
